Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - SC Read more about Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - SC
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG Read more about argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates - SC Read more about Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates - SC
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - SC Read more about Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - SC
再鼎医药公布新临床前数据 显示IL-13/IL-31Rα双特异性抗体ZL-1503在特应性疾病中可快速缓解瘙痒并减轻炎症 Read more about 再鼎医药公布新临床前数据 显示IL-13/IL-31Rα双特异性抗体ZL-1503在特应性疾病中可快速缓解瘙痒并减轻炎症
再鼎医药公布最新数据，显示Zocilurtatug Pelitecan (Zoci) 在小细胞肺癌脑转移患者中实现快速且显著的颅内缓解，并在其他神经内分泌癌中展现出良好活性 Read more about 再鼎医药公布最新数据，显示Zocilurtatug Pelitecan (Zoci) 在小细胞肺癌脑转移患者中实现快速且显著的颅内缓解，并在其他神经内分泌癌中展现出良好活性
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas - SC Read more about Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas - SC
再鼎医药宣布达成全球临床研究合作及供应协议，以评估创新性DLL3抗体药物偶联物Zocilurtatug Pelitecan与双特异性T细胞衔接器的联合治疗 Read more about 再鼎医药宣布达成全球临床研究合作及供应协议，以评估创新性DLL3抗体药物偶联物Zocilurtatug Pelitecan与双特异性T细胞衔接器的联合治疗
再鼎医药将于2026年美国癌症研究协会（AACR）年会上公布三款内部开发肿瘤候选药物的最新数据 Read more about 再鼎医药将于2026年美国癌症研究协会（AACR）年会上公布三款内部开发肿瘤候选药物的最新数据